Navigation Links
Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research

Bcl-2 Antagonist shown to be therapeutically effective in a mouse model of Chronic Lymphocytic Leukaemia

COPENHAGEN, 18 April 2007 - Santaris Pharma, the Danish biopharmaceutical company developing RNAi drugs, yesterday presented encouraging data at the American Association for Cancer Research Annual Meeting in Los Angeles, showing that SPC2996, the Company's RNA Antagonist of Bcl-2, is therapeutically active in a preclinical model of human Chronic Lymphocytic Leukaemia (CLL).

In collaboration with scientists at the University of Duisberg-Essen in Germany, Santaris researchers reported that white blood cells obtained from CLL patient peripheral blood can be transplanted into immunodeficient mice and reliable engraftment of human CLL cells achieved in the spleen, resulting in focal aggregates of B-lymphocytes carrying surface markers characteristic of CLL cancer cells.

SPC2996 was tested for anti-leukaemic activity over two weeks in this model starting two weeks after transplantation and compared for efficacy with multiple doses of fludarabine, a standard chemotherapy for CLL, as well as a negative control oligonucleotide drug similar to but of different sequence from SPC2996. Therapy with SPC2996 resulted in a 54% reduction (p=0.043) in the number of CLL cells which could be recovered from the spleens of the treated transplanted animals compared to animals not receiving therapy. Fludarabine was also effective in the model whereas the negative control drug was not.

This is the first time that primary CLL cells taken from patient blood have been successfully transplanted and shown long term splenic engraftment in an animal model. The model appears to be validated by the efficacy of the fludarabine in clearing engrafted human CLL cells. The demonstration that single agent therapy with SPC2996, a non-chemotoxic agent inhibiting Bcl-2 expression, also clears CLL cells from splenic engraft ment sites is highly encouraging.

SPC2996 is currently in international human Phase I/II studies in CLL. Results of the first clinical study will be presented at the 2007 Annual Meeting of the American Society of Clinical Oncology, June 1-5.

- ENDS -

For further information, please contact:

Dr. Keith McCullagh

President & CEO, Santaris Pharma,

Tel: +45 4517 9819, Cell:+44 7939 573548,>

For media relations, contact:

Annabel Entress,> , +44 (0)20 7268 3002

Adam Michael,> , +44 (0)20 7268 3002

Notes to editors

Chronic Lymphocytic Leukaemia

Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in adults in western Europe and North America, new cases occurring at an annual incidence of 3 to 5 per 100,000 persons in the population. The condition occurs primarily in older people with a median age at diagnosis of 66 years. Men are twice as likely as women to develop the disease. The clinical course of the condition varies widely with some patients showing rapid disease progression and early death, despite intensive chemotherapy, and others surviving for decades without any treatment. CLL is characterised by excessive numbers of functionally incompetent long-lived B-lymphocytes (small white blood cells) circulating in the blood, sometimes also causing swelling of lymph nodes, spleen and other organs. The failure of these cancerous B-CLL cells to die is generally thought to be due at least in part to over expression of the Bcl-2 gene characteristic of the disease.

About Bcl-2

The protein Bcl-2, first identified in B-cell lymphoma/leukaemia cells from which its name derives, is one of a family of intracellular proteins regulating cell survival and cell death. Some types of cells in the body, for example blood cells, are programmed to die after a few weeks of life, in the case of blood cells to be replaced in the circulation by fresh cells produced in the bone marrow. This process of programmed cell death is known as apoptosis. Bcl-2 is an apoptosis suppressor protein, i.e. it extends the lifespan of the cell in the presence of normal apoptosis stimuli. The levels of Bcl-2 within the cell are frequently over-expressed in malignant cancers, and this is particularly the case in human chronic lymphocytic leukaemia and lymphoma where it acts to prolong the life of malignant white blood cells. Drugs which lower the concentration of Bcl-2 or inhibit its function may therefore have therapeutic benefit by inducing cancer cell death and removal without resorting to chemotherapy.

About SPC2966

SPC2996 is the first of a portfolio of novel experimental drugs blocking harmful gene expression being designed and developed by Santaris Pharma. The drug belongs to a new class of drugs called RNA Antagonists, proprietary to Santaris Pharma, based on the novel three-dimensional analogue of RNA known as Locked Nucleic Acid (LNA). The drug binds with high potency and specificity to the messenger RNA for Bcl-2 and destroys it within the cell, resulting in a reduction in Bcl-2 protein concentration. SPC2996 is an investigational product which has not yet been approved by any regulatory agency as effective or safe for patient use but the novel agent is currently being evaluated in international Phase I/II studies in human CLL in centres in Denmark, France, UK and the USA.

AACR Abstract

An Abstract of the work described in this release can be found on the American Association for Cancer Research (AACR) 2007 Annual Meeting database at th e following location: ={188066EA-1D6A-4A42-A0B8-0E27B5DA8D33}&SKey={F80F5B70-96B7-4FF9-A8FF-96 3E225CBA20}&MKey={E3F4019C-0A43-4514-8F66-B86DC90CD935}&AKey={728BCE9C-1 21B-46B9-A8EE-DC51FDFC6C15} < y=%7b188066EA-1D6A-4A42-A0B8-0E27B5DA8D33%7d&SKey=%7bF80F5B70-96B7-4FF9- A8FF-963E225CBA20%7d&MKey=%7bE3F4019C-0A43-4514-8F66-B86DC90CD935%7d&AKe y=%7b728BCE9C-121B-46B9-A8EE-DC51FDFC6C15%7d>

About Santaris Pharma

Santaris Pharma is a clinical-stage biopharmaceutical company focused on developing a new class of RNAi drugs intended to switch off the expression of harmful genes. Called RNA Antagonists, these new drugs are being developed by Santaris and its corporate partners for the treatment of cancer and metabolic disorders. Created in May 2003 and backed by a broad group of leading international life science venture capital investors, Santaris Pharma completed a Euro 40m second round of equity financing in May 2006. In July 2006, the Company entered into a global partnership with Enzon Pharmaceuticals of New Jersey to co-develop and commercialise a series of Santaris RNA Antagonists for improving the treatment of cancer.

Santaris Pharma's RNA Antagonist drug pipeline is based on its unique Locked Nucleic Acid (LNA) technology. LNA drugs, with their high potency and biostability, have the potential to transform the field of RNAi medicines, making specific and effective gene silencing a reality in human medicine. If this potential is realised, even in part, it may be possible to design new drugs to treat the underlying genetic causes of disease rather than just the physical s ymptoms. Santaris Pharma holds the world wide patent rights to the exploitation of LNA in pharmaceuticals and presently has three drugs in preclinical or clinical development. The lead drug candidate, SPC2996, is currently undergoing international, multicenter, phase I/II clinical studies in Chronic Lymphocytic Leukaemia.

For further company information see <>

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should", "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the timing, success and cost of clinical studies; the ability to obtain regulatory approval of products, market acceptance of and future demand for Santaris products and the impact of competitive products and pricing. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Santaris does not intend to update this information.

Best regards

Annabel Entress Account Manager --------------------------------------------- Direct line: +44 (0)20 7268 3234

Main tel: +44 (0)20 7268 3002 Fax: +44 (0)20 7268 3102

Please note our new contact details:

85 Totte nham Court Road, London, W1T 4TQ <>


Related medicine technology :

1. Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):